Committed to Amyloid Research, Lilly Expands its Collaboration with AstraZeneca
By Natasha Berry & Jawala Prasad
Pharma Deals Review: Vol 2016 Issue 12 (Table of Contents)
Published: 24 Dec-2016
DOI: 10.3833/pdr.v2016.i12.2213 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Lilly and existing partner AstraZeneca have agreed to co-develop a Phase I immunotherapy targeting neurotoxic amyloid-β peptide, MEDI1814, for Alzheimer's disease (AD)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS